Valeant prices psoriasis treatment Siliq at $3500 per month in US

Valeant Pharmaceuticals announced Friday that the list price for its recently approved psoriasis treatment Siliq (brodalumab) will be $3500 per month in the US. The company said the price, which has been evaluated by its patient access and pricing committee, makes Siliq "the lowest injectable biologic psoriasis treatment currently on the market."

Valeant created its patient access and pricing committee last year to oversee pricing for its products. The move came after the drugmaker was scrutinised for aggressively raising the prices of the cardiovascular drugs Isuprel (isoproterenol) and Nitropress (nitroprusside).

FirstWord reports in this therapy area - KOL Insight Psoriasis: Find out how KOLs expect the market to evolve, which pipeline treatments are most promising, and which clinical trials will shape treatment decisions. Learn more.

The company was granted an exclusive licence in 2015 to develop and commercialise Siliq from AstraZeneca in a deal worth up to $445 million. The agreement was later amended to terminate Valeant's rights to the drug in Europe. The Canadian drugmaker indicated that sales and marketing of Siliq in the US are expected to start in the second half of 2017.

For related analysis, see ViewPoints: Valeant's Siliq likely to be used as a last-resort biologic therapy, say psoriasis KOLs, and also Physician Views Poll Results: REMS programme, rather than suicide-link, will curtail use of Valeant's Siliq for psoriasis, say dermatologists.

To read more Top Story articles, click here.